Dr. Aquilante's patient-oriented clinical research program is aimed at identifying pharmacogenetic determinants of drug disposition, response, and adverse effects in cardiovascular and metabolic diseases. Her research has been funded by the National Institutes of Health, American Heart Association, American College of Clinical Pharmacy, American Association of Colleges of Pharmacy, pharmaceutical industry, and private foundations.
Education, Licensure & Certifications
- PharmD, University of North Carolina at Chapel Hill
- Pharmacy Practice Residency, Shands Hospital at the University of Florida
- Post-PharmD Research Fellowship in Cardiovascular Pharmacogenomics, University of Florida College of Pharmacy
- Certificate in Clinical Science, University of Colorado Clinical Science Graduate Program
- Cardiovascular Diseases
- Clinical Pharmacogenomics
- Heart Transplantation
Publications and Presentations
Deininger KM, Vu A, Page II, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016; 30(9):1074-8.
Cobretti MR, Page RL 2nd, Linnebur SA, Deininger KM, Ambardekar AV, Lindenfeld J, Aquilante CL. Medication regimen complexity in ambulatory older adults with heart failure. Clin Interv Aging. 2017: 12:679-686
Deininger KM, Page RL 2nd, Lee YM, Kauffman YS, Johnson SG, Oreschak K, Aquilante CL.
Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine. Per Med. 2019; 16(2):123-132.